HK1244440A1 - 癌症對通過pd-1阻斷實現的免疫療法響應的決定因素 - Google Patents

癌症對通過pd-1阻斷實現的免疫療法響應的決定因素

Info

Publication number
HK1244440A1
HK1244440A1 HK18103939.8A HK18103939A HK1244440A1 HK 1244440 A1 HK1244440 A1 HK 1244440A1 HK 18103939 A HK18103939 A HK 18103939A HK 1244440 A1 HK1244440 A1 HK 1244440A1
Authority
HK
Hong Kong
Prior art keywords
blockade
determinants
immunotherapy
cancer response
cancer
Prior art date
Application number
HK18103939.8A
Other languages
English (en)
Inventor
Timothy A Chan
Naiyer A Rizvi
Matthew D Hellman
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of HK1244440A1 publication Critical patent/HK1244440A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18103939.8A 2014-11-21 2018-03-21 癌症對通過pd-1阻斷實現的免疫療法響應的決定因素 HK1244440A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US201562132381P 2015-03-12 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Publications (1)

Publication Number Publication Date
HK1244440A1 true HK1244440A1 (zh) 2018-08-10

Family

ID=56014697

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103939.8A HK1244440A1 (zh) 2014-11-21 2018-03-21 癌症對通過pd-1阻斷實現的免疫療法響應的決定因素

Country Status (9)

Country Link
US (3) US20180291074A1 (zh)
EP (1) EP3220950A4 (zh)
JP (3) JP7173733B2 (zh)
CN (2) CN107206064B (zh)
AU (2) AU2015349644B2 (zh)
CA (1) CA2968059A1 (zh)
HK (1) HK1244440A1 (zh)
MA (1) MA40737A (zh)
WO (1) WO2016081947A2 (zh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
MX2018010361A (es) * 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
EP3423488A4 (en) 2016-02-29 2019-11-06 Foundation Medicine, Inc. METHOD FOR THE TREATMENT OF CANCER
JP6918816B2 (ja) * 2016-03-01 2021-08-18 ノース カロライナ ステート ユニバーシティ マイクロニードルパッチ支援送達による強化されたがん免疫療法
KR102356961B1 (ko) * 2016-03-02 2022-01-28 도레이 카부시키가이샤 면역 유도제
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
EP3500966B1 (en) * 2016-08-25 2021-04-21 Nantomics, LLC Immunotherapy markers and uses therefor
MX2019003934A (es) * 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
US11515008B2 (en) 2016-10-07 2022-11-29 Omniseq, Inc. Methods and systems for determining personalized t'herapies
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018145023A1 (en) * 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
CN110651036A (zh) * 2017-03-20 2020-01-03 健诺西生物科学公司 治疗方法
BR112019019795A2 (pt) * 2017-03-31 2020-04-22 Bristol-Myers Squibb Company métodos para tratar tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
US11674962B2 (en) * 2017-07-21 2023-06-13 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2019023624A1 (en) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
CA3073531A1 (en) * 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
EP4226944A3 (en) 2017-09-25 2023-10-25 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
EP3691676A4 (en) * 2017-10-02 2021-06-16 Curematch, Inc. METHOD FOR PREDICTING ANTIGENICITY AND / OR IMMUNOGENICITY OF A TUMOR-DERIVED NEO-PEPTIDE, USING MUTATIONAL SIGNATURE GROUNDS
CN111465989A (zh) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 使用热点进行的新抗原鉴别
CN111213209A (zh) * 2017-10-12 2020-05-29 南托米克斯有限责任公司 根据生物体液的评估用癌症评分和反应预测
CN111247169A (zh) * 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
AU2018367925A1 (en) * 2017-11-17 2020-07-02 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019109086A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
EP3788173B1 (en) 2018-05-03 2023-11-29 F. Hoffmann-La Roche AG Surrogate marker and method for tumor mutation burden measurement
BR112020022145A2 (pt) * 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
SG11202100344WA (en) 2018-07-23 2021-02-25 Guardant Health Inc Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
US20210292851A1 (en) 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
JPWO2020045479A1 (ja) * 2018-08-29 2021-08-12 公益財団法人東京都医学総合研究所 ＨＧＦ−ｒｅｇｕｌａｔｅｄ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ ｓｕｂｓｔｒａｔｅ（ＨＧＳ）を標的とした抗腫瘍剤
AU2019328344A1 (en) 2018-08-31 2021-04-08 Guardant Health, Inc. Microsatellite instability detection in cell-free DNA
CA3120200A1 (en) * 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
US20200190598A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in nsclc
WO2020252456A1 (en) * 2019-06-14 2020-12-17 The Trustees Of Columbia University In The City Of New York Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
CN112309502A (zh) * 2020-10-14 2021-02-02 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
WO2022235482A1 (en) * 2021-05-03 2022-11-10 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
WO2011060328A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CA2796571C (en) * 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
WO2014052707A2 (en) * 2012-09-28 2014-04-03 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
SG11201605432RA (en) * 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
CA2966660A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
EP4226944A3 (en) * 2017-09-25 2023-10-25 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Also Published As

Publication number Publication date
CA2968059A1 (en) 2016-05-26
WO2016081947A4 (en) 2016-09-09
WO2016081947A3 (en) 2016-07-07
AU2015349644B2 (en) 2021-08-19
AU2021215099A1 (en) 2021-08-26
JP2023055625A (ja) 2023-04-18
JP7173733B2 (ja) 2022-11-16
US20180291074A1 (en) 2018-10-11
JP2018502828A (ja) 2018-02-01
US10993998B2 (en) 2021-05-04
CN107206064B (zh) 2021-12-21
JP2020196732A (ja) 2020-12-10
CN114672559A (zh) 2022-06-28
WO2016081947A2 (en) 2016-05-26
US20210308241A1 (en) 2021-10-07
CN107206064A (zh) 2017-09-26
MA40737A (fr) 2017-07-04
US20200040049A1 (en) 2020-02-06
EP3220950A4 (en) 2018-08-29
AU2015349644A1 (en) 2017-06-15
EP3220950A2 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
HK1244440A1 (zh) 癌症對通過pd-1阻斷實現的免疫療法響應的決定因素
IL267798B (en) Human antibodies to pd-1
SG11201605432RA (en) Determinants of cancer response to immunotherapy
IL273230A (en) Preparation of carbamoylpyridone-polycyclic compounds
IL253013B (en) Antibodies to tigit
HK1252666A1 (zh) 針對cd40的抗體
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
ZA201701246B (en) Synthesis of dna
SG11201606443WA (en) Synthesis of framework modified zsm-48 crystals
EP3516081A4 (en) DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
HK1208220A1 (zh) 種 -烯丙基喜樹鹼衍生物的合成方法
GB201416951D0 (en) Method of synthesis
TH1601001556A (th) วิธีการผลิตผงเครื่องดื่มกาแฟ
AU2014902720A0 (en) Methods to Increase Tuber Yield
TWM489117U (en) Improved structure of cart